ProShare Advisors
NAGE

ProShare Advisors’s Niagen Bioscience NAGE Stock Holding History

ProShare Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,707
Closed -$154K – 2130
2025
Q2 		$154K Sell
10,707
-10
-0.1% -$99 ﹤0.01% 1782
2025
Q1 		$73.9K Sell
10,717
-3,228
-23% -$20.3K ﹤0.01% 1891
2024
Q4 		$74K Buy
+13,945
New +$76.3K ﹤0.01% 2123
2022
Q1 		– Sell
-10,240
Closed -$38K – 2316
2021
Q4 		$38K Buy
+10,240
New +$55.3K ﹤0.01% 2313
2021
Q3 		– Sell
-12,158
Closed -$120K – 2297
2021
Q2 		$120K Buy
12,158
+1,111
+10% +$9.69K ﹤0.01% 2268
2021
Q1 		$103K Buy
+11,047
New +$87.6K ﹤0.01% 2161

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ProShare Advisors's NAGE Position: Q3 2025 in Review

ProShare Advisors sold out of Niagen Bioscience (NAGE) in Q3 2025, closing a stake of 10,707 shares — an estimated $154K sold.

ProShare Advisors first reported a position in NAGE in Q1 2021 and held it in 6 quarters. The position peaked at $154K in Q2 2025. 162 funds tracked by Wall St. Rank hold NAGE as of Q3 2025.

  • ProShare Advisors reported no remaining Niagen Bioscience position as of Q3 2025 after selling out during the quarter.
  • ProShare Advisors sold 10,707 Niagen Bioscience shares in Q3 2025, an estimated $154K.
  • ProShare Advisors first reported a position in Niagen Bioscience in Q1 2021 and held it in 6 quarters.
  • ProShare Advisors's Niagen Bioscience position peaked at $154K in Q2 2025.
  • 162 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2025.

Based on ProShare Advisors's 13F filing for Q3 2025, filed 6 Nov 2025.